Showing posts with label (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide). Show all posts
Showing posts with label (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide). Show all posts

Friday, March 13, 2015

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101



Methyl 1 N6 3 Iodobenzyl Adenin 9 Yl B D Ribofuronamide Drug



Can-Fite BioPharma Ltd.  a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101. Dr. M. Silverman, Can-Fite Medical Director, and Dr. Lee Simon, a key opinion leader in the field of autoimmune inflammatory diseases, designed the Phase III clinical study.

The Phase III study will be a multicenter, randomized, double-blind, placebo-controlled, parallel-group study that will investigate the efficacy and safety of daily CF101 administered orally as a monotherapy for 12 weeks to patients with active RA. The study will have three arms, a 2 mg CF101 dose, a 3mg CF101 dose and placebo, given orally twice daily in the form of tablets. Approximately 300 patients are expected to be enrolled in the study, where sample size for each treatment group will be approximately 100 patients and will provide a statistical power of at least 90%. The study primary end point will be ACR 20 response at Week 12. The A3 adenosine receptor biomarker will be evaluated prior to treatment and its correlation to patients' response to the drug will be analyzed upon study conclusion.